** Medical device maker Adaptive Biotechnologies Corp's ADPT.O shares rise as much as 34.5% to over a year high of $9.9
** Stock is set for its best day since its IPO in 2019, if gains hold
** Late on Thursday, ADPT posted 25% rise in Q1 revenue to $52.44 million, beating analysts' estimates of $42.68 million
** Co reported Q1 net loss of $29.8 million, compared to $47.5 million for the same period in 2024
** Co reported cash, cash equivalents and marketable securities of $232.8 million as of March 31, 2025
** Co expects full year total company cash burn to be between $50 million and $60 million, from the previous range between $60 million and $70 million
** As of last close, ADPT has fallen 62.1% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。